OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Shah on Efforts to Combat Resistance to BTK Inhibitors in MCL

July 7th 2021

Bijal Shah, MD, MS, discusses efforts to combat resistance to BTK inhibitors in patients with mantle cell lymphoma.

Dr. Wong on Treatment Goals in Systemic Amyloidosis

July 7th 2021

Sandy Wong, MD, discusses treatment goals for patients with systemic amyloidosis.

Dr. Phillips on the Next Steps With Venetoclax/Lenalidomide/Rituximab in MCL

July 7th 2021

Tycel Jovelle Phillips, MD, discusses the next steps in evaluating the combination of venetoclax, lenalidomide, and rituximab in mantle cell lymphoma.

Dr. Kahl on Differences in Mechanisms of Action of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

Brad S. Kahl, MD, discusses the differences between mechanisms of action of PI3K inhibitors in follicular lymphoma.

Dr. Leonard on the Future of PI3K Inhibitors in Follicular Lymphoma

July 7th 2021

John P. Leonard, MD, discusses the future of PI3K inhibitors in follicular lymphoma.

Dr. Pemmaraju on Characteristics of Disease Progression in Myelofibrosis

July 7th 2021

Naveen Pemmaraju, MD, discusses the characteristics of disease progression in patients with myelofibrosis.

Dr. Mauro on Managing Symptom Burden in Myelofibrosis

July 6th 2021

Michael J. Mauro, MD, discusses managing symptom burden in patients with myelofibrosis.

Dr. Abedin on the Safety and Efficacy of Ibrutinib in CLL

July 6th 2021

Sameem Abedin, MD, discusses the safety and efficacy of ibrutinib in the treatment of patients with chronic lymphocytic leukemia.

Dr. Leonard on the Potential for Combinations With PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

John P. Leonard, MD, discusses the potential for combination regimens with PI3K inhibitors in follicular lymphoma.

Dr. Kahl on Selecting Between PI3K Inhibitors in Follicular Lymphoma

July 6th 2021

Brad S. Kahl, MD, discusses selecting between PI3K inhibitors in follicular lymphoma.

Dr. Hubbard on the Utility of MRD Assessment for Stage II CRC

July 1st 2021

Joleen M. Hubbard, MD, discusses the utility of minimal residual disease assessment for stage II colorectal cancer.

Dr. Hwang on Considerations for Second-Line Treatment in Gastric/GEJ Cancer

July 1st 2021

Jimmy Hwang, MD, discusses considerations for second-line treatment in gastric/gastroesophageal junction cancer.

Dr. Williams on the Role of PI3K Inhibitors in HR+/HER2- Breast Cancer

July 1st 2021

Nicole O. Williams, MD, discusses the role of PI3K inhibitors in hormone receptor–positive, HER2-negative breast cancer.

Dr. Davies on the Next Steps for CAR T-Cell Therapy in Relapsed/Refractory Myeloma

July 1st 2021

Faith E. Davies, MD, discusses the next steps for CAR T-cell therapy in the treatment of patients with relapsed/refractory multiple myeloma.

Dr. Adams on Tackling Storage and Logistical Challenges in Cell Therapy

June 30th 2021

Julian Adams, PhD, discusses research efforts surrounding GDA-201, including details of the cryo buffer that the company developed in order to efficiently freeze and recover the GDA-201 cells.

Dr. Adams on Improving Bone Marrow Transplant With Omidubicel

June 30th 2021

Julian Adams, PhD, discusses approaches to cell therapy, and the potential of omidubicel as an alternative to bone marrow transplant in leukemias and lymphomas.

Dr. Ailawadhi on Next Steps With Lisaftoclax in CLL

June 30th 2021

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Dr. Byrd on Future Directions With Acalabrutinib in CLL

June 30th 2021

John C. Byrd, MD, discusses future directions with acalabrutinib in chronic lymphocytic leukemia.

Dr. Barr on the Rationale for the Long-Term Evaluation of the RESONATE-2 Trial in CLL

June 30th 2021

Paul M. Barr, MD, discusses the rationale for the long-term analysis of the phase 3 RESONATE-2 trial in chronic lymphocytic leukemia.

Dr. Nadeem on the Integration of Isatuximab in Relapsed/Refractory Multiple Myeloma

June 29th 2021

Omar Nadeem, MD, discusses the integration of isatuximab-irfc in relapsed/refractory multiple myeloma.